Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Xometry, Inc. (NASDAQ: XMTR) announced record second quarter 2026 results highlighted by 41% year-over-year revenue growth to $229 million, with marketplace revenue increasing 45%. Gross profit rose 34% to $87.2 million, and Adjusted EBITDA improved significantly to $14.1 million, driven by the company's AI-native marketplace expansion, network gro…
Superior Group of Companies, Inc. announced its second quarter 2026 financial results, reporting net sales of $147.8 million, a slight increase from the prior year. Despite a non-cash tradename impairment charge impacting net income to $1.2 million, adjusted net income rose to $3.2 million with adjusted EPS doubling year-over-year. The company conf…
SK hynix rallied in pre-market trading after detailing a new High Bandwidth Flash (HBF) standard with SanDisk at FMS 2026 and disclosing its tenth-generation V10 375-layer 4D NAND. The announcement, which positions HBF between HBM and SSDs for AI inference workloads, plus upbeat analyst initiations and a firmer macro backdrop, drove a notable pre-o…
IREN Limited has completed the acquisition of Mirantis, a cloud software and services provider, enhancing IREN's AI workload orchestration, monitoring, and customer support capabilities. This acquisition strengthens IREN’s vertically integrated AI Cloud platform by combining their owned data centers and compute infrastructure with Mirantis' robust …
Invivyd, Inc. announced the grant of stock options totaling 277,500 shares to ten newly hired non-executive employees as inducements under Nasdaq Listing Rule 5635(c)(4). These options have an exercise price of $0.535, matching the stock's closing price on July 31, 2026, with a four-year vesting period and a 10-year term. This move aims to attract …
Rhythm Pharmaceuticals announced its Q2 2026 financial results, highlighting a robust U.S. launch of IMCIVREE for acquired hypothalamic obesity, with over 400 patient starts since FDA approval. Net product revenue reached $71.3 million globally, a 19% sequential increase, driven by strong U.S. sales and growing patient reimbursement. The company al…
Larimar Therapeutics reported encouraging long-term safety and efficacy data for nomlabofusp in an open-label study for Friedreich's ataxia, submitted the first module of a rolling Biologics License Application with the FDA seeking accelerated approval, and plans to start a global Phase 3 confirmatory study in Q3 2026. The company has a strong cash…
Descartes Systems Group will announce its second quarter fiscal 2027 financial results after market close on September 10, 2026. The company's executive management will host a conference call and webcast to discuss the results, providing investors and stakeholders with insight into its performance in the logistics technology sector.
RYTHM, Inc. reported robust financial results for Q2 2026, with revenue from continuing operations reaching $23 million, up 73% quarter-over-quarter. The company achieved net income of $1.2 million and an adjusted EBITDA of $6.4 million, marking a significant turnaround from breakeven in the prior quarter. Growth in THC beverage shipments and new s…
Aclarion, Inc. announced that its Nociscan platform for identifying the source of chronic low back pain is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, the first site in Indiana to offer this technology. This expansion marks growth in Aclarion's provider network and aligns the company with a nationally recognized neuros…
iBio, a clinical-stage biotechnology company focused on long-acting antibody therapeutics for obesity and cardiometabolic diseases, has appointed Dr. Molly Carr as Chief Medical Officer. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, having held senior roles at major biopharmaceutical companies. Her leadership i…
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focusing on novel FASN inhibitors targeting metabolic and fibrotic pathways, announced management's participation in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026.
CAMP4 Therapeutics completed the second closing of a $100 million private placement, raising approximately $50.1 million to fund clinical development of CMP-002, a lead antisense oligonucleotide targeting SYNGAP1-related disorder, and other early-stage programs. The company aims to initiate a Phase 1/2 trial in Australia, advancing its pipeline of …
Shoals Technologies Group, Inc., a leader in electrical infrastructure solutions for the energy transition, reported strong Q2 2026 financial results, with revenue increasing 47.4% to $163.4 million and a record backlog and awarded orders of $801.4 million. Although gross margin declined primarily due to operational inefficiencies from transitionin…
X-Energy's subsidiary TRISO-X has acquired an additional 70 acres adjacent to its Oak Ridge, Tennessee nuclear fuel campus, expanding its total footprint to approximately 180 acres. This expansion supports construction and long-term growth plans for advanced nuclear fuel fabrication facilities and research capabilities, reinforcing the region’s lea…
First Watch Restaurant Group, Inc. released its Q2 2026 financial results, highlighting a 15.2% increase in total revenues to $354.7 million, same-restaurant sales growth of 3.4%, and net income rising to $2.3 million. The company opened 18 new restaurants and updated its fiscal 2026 outlook projecting revenue growth between 12.5% to 14%, and adjus…
Arvinas, Inc. announced the FDA approval of VEPPANU, the first-ever PROTAC degrader approved for breast cancer treatment, and completed a global licensing deal with Rigel Pharmaceuticals. The company reported strong financial results for Q2 2026, driven by increased revenues from partnerships and milestones. Clinical progress includes ongoing Phase…
Odyssey Therapeutics reported its second quarter 2026 results, highlighting positive Phase 2a trial data for its OD-001 program to be presented at a major gastroenterology conference in October. The company plans to initiate Phase 2b monotherapy and Phase 2a combination trials for OD-001 in the second half of 2026, alongside preparing a CTA filing …
TOP Financial Group Limited announced a major strategic initiative to incorporate advanced artificial intelligence technologies across its core brokerage and financial technology businesses. The company plans to develop AI infrastructure encompassing software, hardware, cloud computing, and AI agent deployment to enhance operational efficiency, use…
Insight Molecular Diagnostics Inc. announced it will release its second quarter 2026 financial results on August 10, 2026, followed by a live webinar to discuss the results. The company will also participate in the 11th Annual Needham Virtual MedTech & Diagnostics conference on August 11, 2026, holding one-on-one investor meetings virtually.
Strata Critical Medical, Inc. announced second-quarter 2026 financial results, showing a 60.7% year-over-year revenue increase to $72.5 million. The growth was fueled by organic expansion in logistics and significant contributions from recent clinical business acquisitions. Adjusted EBITDA nearly tripled year-over-year to $7.9 million, with margin …
Aeluma, a NASDAQ-listed semiconductor company, announced the appointment of Jason Taylor as Senior Director of Program and Project Management. With nearly 30 years of semiconductor experience, Taylor will lead program management efforts to commercialize Aeluma's compound semiconductor photonic technologies. This strategic hire comes amid growing co…
Lisata Therapeutics announced the termination of its merger agreement with Kuva Labs and has filed a lawsuit against Kuva for breach of contract seeking damages and a termination fee. The company is actively evaluating strategic alternatives to maximize shareholder value, including possible mergers, acquisitions, asset sales, or liquidation. To con…
Beam Therapeutics announced significant progress in Q2 2026, including dosing the first patient in a pivotal cohort for BEAM-302 in alpha-1 antitrypsin deficiency, completion of dosing in the BEACON trial for sickle cell disease with risto-cel, FDA clearance for BEAM-304 clinical trial in phenylketonuria, and a strong cash position supporting opera…
Certara, Inc. reported a 1% increase in total revenue year-over-year for Q2 2026, with software revenue growing 4% while services revenue declined 3%. The company posted a net loss of $6.1 million due to higher operating expenses and absence of prior year favorable adjustments. Certara completed a $100 million share repurchase program and authorize…
